

STRONG COHORT 4 TESTING DATA DEMONSTRATES VALUE OF BCAL TEST

- **New scientific data strongly reinforces previous results**
- **Value of 18 candidate lipid biomarker panel in diagnosing breast cancer confirmed**
- **Potential for acceleration of commercial use of test**
- **Patient recruitment underway for new clinical study – successful recruitment of 150 patients to date**
- **Clinical study sites continue to expand**

Breast cancer screening and diagnostic company BCAL Diagnostics (ASX:BDX, 'BCAL' or the 'Company') is pleased to announce that it has completed the processing of 301 samples as part of its Cohort 4 testing, with the positive results having the potential to accelerate development of BCAL's test.

The clinical data and results of the combined Cohort 4 and Cohort 3 testing are in alignment with previously reported specificity and accuracy of the test in early-stage detection of breast cancer. Reproducing these results to such a high standard reinforces the continued scientific development and advancement of the science by BCAL's team. The results are based on the 18 candidate lipid marker panel, as previously identified, with pathways to accelerate development of the test showing significant potential.

The data analysis is continuing as BCAL seeks to further refine its algorithm and biomarker development. BCAL has also appointed an international consulting group, with a wealth of relevant international expertise in the development of in vitro diagnostic products, to assist with algorithm optimisation.

With the scientific progress continuing on course, BCAL is actively recruiting patients for the Stage I clinical trial of the test, with 150 already secured. Patients are currently being recruited at clinical study sites including Sydney Breast Clinic and Chris O'Brien Lifehouse, with BreastScreen NSW to commence upon reopening post lockdown measures.

Executive Chair Jayne Shaw commented: *"The results from Cohort 4 have strengthened the scientific data and support the continued validation of the biomarker panel for clearly identifying blood samples that come from breast cancer patients in our cohorts."*

This result signals successful achievement of the first milestone set out by the Company at its IPO, and paves the way for progressing work on Cohort 5, the next stage in clinical validation of the BCAL test."

This ASX announcement has been approved for release by the Board of BCAL Diagnostics Limited.

ENDS

Investor & Media Enquiries

Matthew Wright
NWR Communications
matt@nwrcommunications.com.au
+61 451 896 420

About BCAL Diagnostics

BCAL Diagnostics Limited is an Australian screening and diagnostic company committed to the early, accurate diagnosis of breast cancer, and therefore early intervention and improved outcomes for women. Over the past decade BCAL has developed a non-invasive blood test for the detection of breast cancer, with results to date demonstrating 91% specificity and 87% accuracy. The test is initially designed to complement current imaging technologies, such as the mammogram, with the aim of becoming a monitoring and screening tool suitable for women of all ages and backgrounds in any location. With more than two million new cases of breast cancer diagnosed globally each year, a substantial opportunity exists for BCAL to improve patient outcomes. BCAL has partnered with global integrated cancer care and cardiac provider GenesisCare to conduct clinical research required for regulatory approvals across several jurisdictions, commercialisation and market entry points.

Founded in 2010, BCAL is headquartered in Sydney and listed on the Australian Securities Exchange (ASX:BDX). For more information: <https://www.bcaldiagnostics.com/>